Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry-Guided Breathing Therapy - Phase 2

9 de novembro de 2026 atualizado por: Pervez Sultan, Stanford University

Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry Guided Breathing Therapy - Phase 2

The purpose of this study is to evaluate the feasibility, acceptability, and preliminary effectiveness of two early interventions, Written Exposure Therapy (WET) and Capnometry-Guided Breathing Intervention (CGRI), for reducing post-traumatic stress disorder (PTSD) symptoms following childbirth, compared with usual care.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

60

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • University of Arkansas for Medical Sciences
        • Contato:
    • California
      • Palo Alto, California, Estados Unidos, 94304
        • Stanford University
        • Contato:
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Age ≥18
  • Delivered a live infant within 5 days
  • Severe maternal morbidity or infant admitted to NICU
  • PCL-5 ≥28
  • English-speaking
  • Able to consent and participate

Exclusion Criteria:

  • Active psychosis or mania
  • Current suicidal crisis
  • Current suicidal intent or plan

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Written Exposure Therapy (WET)

Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision.

Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision.

Experimental: Capnometry-Guided Breathing Intervention (CGRI)

Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff.

Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff.

Sem intervenção: Postpartum Standard of Care

Participants will follow their current standard of care.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentagem de participantes que completaram a Terapia de Exposição Escrita (WET)
Prazo: Da Linha de Base à Semana 6
Da Linha de Base à Semana 6
Percentagem de adesão à Terapia de Exposição Escrita (WET)
Prazo: Baseline até à Semana 6
Baseline até à Semana 6
Percentagem de participantes que completaram a Intervenção Respiratória Guiada por Capnometria (CGRI)
Prazo: Baseline para Semana 6
Baseline para Semana 6
Percentagem de adesão à Intervenção Respiratória Guiada por Capnometria (CGRI)
Prazo: Baseline para a Semana 6
Baseline para a Semana 6
Percentage of participants initiating assigned treatment
Prazo: Baseline (up to 2 weeks)

Proportion of participants who begin their assigned intervention (≥1 session for WET; completion of initial training for CGRI)

Baseline (up to 2 weeks)
Participant Satisfaction Scale Score using Client Satisfaction Questionnaire (CSQ-8)
Prazo: Week 5

Participant satisfaction measured using the CSQ-8 questionaire, an 8-item scale. (Scale score 8 - 32. Higher scores represent greater satisfaction with treatment.)

Week 5
Treatment credibility using the Opinion About Treatment (OAT) form
Prazo: Week 5

Participant perceptions of treatment credibility will be measured using the OAT form. (Scale score 3 - 27. Higher scores represent greater perceived credibility of the intervention.)

Week 5

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change from baseline in PTSD Checklist for DSM-5 (PCL-5) Scale Score
Prazo: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12

Change in PTSD symptoms during past week measured by the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report measure. (Score range 0 - 80, higher scores indicating greater severity of PTSD symptoms.).

Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
Change from baseline in Edinburgh Postnatal Depression Scale (EPDS) Scale Score
Prazo: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12

Participants complete the EPDS questionnaire, a 10-item scale assessing postpartum depressive symptoms over the past 7 days. (Score range 0 - 30, higher scores represents greater symptom severity.)

Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
Change from baseline in Whole Person Health Index (WPHI) Scale Score
Prazo: Baseline, Week 3, Week 6, Week 12

Participants complete WHPI questionaire, a 9 item scale assessing global health and functioning. (Score range 9 - 81, higher scores represent better health).

Baseline, Week 3, Week 6, Week 12
Change from baseline in Generalized Anxiety Disorder Questionaire (GAD-7)
Prazo: Baseline, Week 3, Week 6, Week 12

Participants complete the GAD-7, a 7-item scale assessing anxiety symptoms over 2 weeks. (Score range 0 - 21, higher scores represent greater anxiety severity.)

Baseline, Week 3, Week 6, Week 12
Change from baseline in Maternal-infant bonding (MIBS) Scale Score
Prazo: Baseline, Week 3, Week 6, Week 12

Participants complete the MIBS questionaire, an 8 item measure of bonding difficulties over the past few weeks (Score range 0 - 24, higher scores represent greater bonding impairment).

Baseline, Week 3, Week 6, Week 12
Change from baseline in STanford Obstetric Recovery checKlist (STORK) scale score
Prazo: Baseline, Week 3, Week 6, Week 12

Participants complete the STORK questionnaire, a 47-item scale assessing postpartum recovery over the past 7 days. (Score range 0 - 188, higher score represents a greater degree of recovery)

Baseline, Week 3, Week 6, Week 12
Change from baseline in Breastfeeding Self-Efficacy Scale-Short Form (BFSES-SF)
Prazo: Baseline, Week 3, Week 6, Week 12

Participants complete the BFSES-SF, a 14-item measure of breastfeeding self-efficacy (Score range 14 - 70, higher scores indicate greater breastfeeding confidence.)

Baseline, Week 3, Week 6, Week 12
Percentage of participants completing hair sample collection at Baseline and Week 6
Prazo: Baseline, Week 6

Participants have hair samples collected at baseline and at Week 6 post treatment.

Baseline, Week 6
Change in hair cortisol concentration between Baseline and Week 6
Prazo: Baseline, Week 6

Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisol concentration from Baseline to Week 6

Baseline, Week 6
Change in hair cortisone concentration between Baseline and Week 6
Prazo: Baseline, Week 6

Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisone concentration from Baseline to Week 6

Baseline, Week 6
Change in hair testosterone concentration between Baseline and Week 6
Prazo: Baseline, Week 6

Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair testosterone concentration from Baseline to Week 6

Baseline, Week 6
Change in hair progesterone concentration between Baseline and Week 6
Prazo: Baseline, Week 6

Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair progesterone concentration from Baseline to Week 6

Baseline, Week 6
Change in hair corticosterone concentration between Baseline and Week 6
Prazo: Baseline, Week 6

Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair corticosterone concentration from Baseline to Week 6

Baseline, Week 6
Change in hair dehydroepiandrosterone (DHEA) concentration between Baseline and Week 6
Prazo: Baseline, Week 6

Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair dehydroepiandrosterone (DHEA) concentration values from Baseline to Week 6

Baseline, Week 6
Change in hair androstenedione concentration between Baseline and Week 6
Prazo: Baseline, Week 6

Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair androstenedione concentration from Baseline to Week 6

Baseline, Week 6

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Pervez Sultan, Stanford University
  • Investigador principal: Debra Kaysen, Stanford University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de fevereiro de 2027

Conclusão Primária (Estimado)

1 de janeiro de 2028

Conclusão do estudo (Estimado)

1 de fevereiro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

9 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de novembro de 2026

Primeira postagem (Real)

16 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 80498-2
  • R01AT013866-01 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Prazo de Compartilhamento de IPD

Beginning 9 months and ending 36 months following article publication.

Critérios de acesso de compartilhamento IPD

Wish whom? Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For what types of analysis? For individual participant data meta-analysis By what mechanism will data be made available? Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be provided).

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .